News | January 06, 2022
Margins under pressure; domestic market growth to slow down: Nirmal Bang
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
Biogen paid Ionis a US $ 60 million one-time upfront payment
The combination enhances Comar's customer value proposition by adding complementary closure and jar products and related precision mold-making expertise
This product will be manufactured at Lupin's Goa facility in India
Flattish volume growth and subdued new launches were key factors for last month
He has over 22 years of experience in pharmaceutical sales & business development
It is indicated for the treatment of patients with acromegaly and Gastroenteropancreatic Neuroendocrine Tumours
It is the first approved generic and is eligible for 180 days of Competitive Generic Therapy exclusivity
Immatics to receive upfront payment of US $ 150 million and additional milestone payments of up to US $ 770 million plus tiered double-digit royalties on net product sales
The cash consideration for the acquisition is US$ 18 million.
Subscribe To Our Newsletter & Stay Updated
